Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population

Pharmacology and Toxicology

Volumn 78, Issue 5, 1996, Pages 303-307

  Marandi, T ^a   Dahl, M L ^b   Kiivet, R A ^a   Rago L ^a   Sjoqvist F ^b  

^a UNIVERSITY OF TARTU   (Estonia)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DEXTROMETHORPHAN; MEPHENYTOIN;

ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; VOLUNTEER;

EID: 0029895951     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1996.tb01379.x     Document Type: Article

References (31)

1. Alvan, G., P. Bechtel, L. Iselius & U. Gundert-Remy: Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 1990, 39, 533-537.
2. Bertilsson, L., Y. Q. Lou, Y. L. Du, Y. Liu, T. Y. Kuang, X. M. Liao, K. Y. Wang, J. Reviriego, L. Iselius & F. Sjöqvist: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin. Pharmacol. Therap. 1992, 51, 388-397.
3. Bertilsson, L., M. L. Dahl, M. Ingelman-Sundberg, I. Johansson & F. Sjöqvist: Interindividual and interethnic differences in polymorphic drug oxidation implications for drug therapy with focus on psychoactive drugs. In: Advances in drug metabolism in man. Eds.: G. M. Pacifici & G. N. Fracchia. European Commission, DG XII - Science, Research and Development, Luxembourg, 1995, p. 85-136.
4. Broly, F., A. Gaedigk, M. Heim, M. Eichelbaum, K. Morike & U. A. Meyer: Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population. DNA and Cell Biology 1991, 10, 545-558.
5. Brøsen, K. & L. F. Gram: Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur. J. Clin. Pharmacol. 1989, 36, 537-549.
6. Brøsen, K., P. N. Nielsen, K. Brusgaard, L. F. Gram & K. Skjødt: CYP2D6 genotype determination in the Danish population. Eur. J. Clin. Pharmacol. 1994, 47, 221-225.
7. Dahl, M. L., I. Johansson, M. Porsmyr Palmerts, M. Ingelman-Sundberg & F. Sjöqvist: Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin. Pharmacol. Therap. 1992, 51, 12-17.
8. Dahl, M. L. & L. Bertilsson: Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993, 3, 61-70.
9. Dahl, M. L., I. Johansson, L. Bertilsson, M. Ingelman-Sundberg & F. Sjöqvist: Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Therap. 1995, 274, 516-520.
10. De Morais, S. M. F., G. R. Wilkinson, J. Blaisdell, K. Nakamura, U. A. Meyer & J. A. Goldstein: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 1994a, 269, 15419-15422.
11. De Morais, S. M. F., G. R. Wilkinson, J. Blaisdell, U. A. Meyer, K. Nakamura & J. A. Goldstein: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 1994b, 46, 594-598.
12. Eichelbaum, M., N. Spannbrucker, B. Steinke & H. J. Dengler: Defective N-oxidation of sparteine in man: a new phamacogenetic defect. Eur. J. Clin. Pharmacol. 1979, 16, 183-187.
13. Eichelbaum, M. & A. S. Gross: The genetic polymorphism of debrisoquin/sparteine metabolism-clinical aspects. In: Pharmacogenetics of drug metabolism. Ed.: W. Kalow. Pergamon Press, New York 1992, p. 625-648.
14. Evans, D. A. P., A. Mahgoub, T. P. Sloan, J. R. Idle & R. L. Smith: A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet. 1980, 17, 102-105.
15. Gaedigk, A., M. Blum, R. Gaedigk, M. Eichelbaum & U. A. Meyer: Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Amer. J. Hum. Genet. 1991, 48, 943-950.
16. Heim, M. & U. A. Meyer: Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990, 336, 529-532.
17. Johansson, I., E. Lundqvist, L. Bertilsson, M. L. Dahl, F. Sjöqvist & M. Ingelman-Sundberg: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. (USA) 1993, 90, 11825-11829.
18. Johansson, I., E. Lundqvist, M. L. Dahl, M. Ingelman-Sundberg: PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996, in press.
19. Kiivet, R. A., J. O. Svensson, L. Bertilsson & F. Sjöqvist: Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians. Pharmacology & Toxicology 1993, 72, 113-115.
20. Kiivet, R. A., A. LLerena, M. L. Dahl, L. Rootslane, J. Sanchez Vega, T. Eklundh & F. Sjöqvist: Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Brit. J. Clin. Pharmacol. 1995, 40, 467-476.
21. Lennard, M. S., J. H. Silas, A. J. Smith & G. T. Tucker: Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame ionization and nitrogen selective detection. J. Chromatogr. 1977, 133, 161-166.
22. LLerena, A., A. G. Herraiz, J. Cobaleda, I. Johansson & M. L. Dahl: Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin. Pharmacol. Therap. 1993, 54, 606-611.
23. Mahgoub, A., J. R. Idle, L. G. Dring, R. Lancaster & R. L. Smith: Polymorphic hydroxylation of debrisoquine in man. Lancet 1977, 2, 584-586.
24. Meyer, U. A., R. C. Skoda, U. M. Zanger, M. Heim & F. Broly: The genetic polymorphism of debrisoquine/sparteine metabolism - molecular mechanisms. In: Pharmacogenetics of drug metabolism. Ed.: W. Kalow. Pergamon Press, New York 1992, p. 609-623.
25. Sanz, E. J., T. Villén, C. Alm & L. Bertilsson: S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine. Clin. Pharmacol. Therap. 1989, 45. 495-499.
26. Schmid, B., J. Bircher, R. Preisig & A. Küpfer: Polymorphic dextromethorphan hydroxylation: Co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin. Pharmacol. Therap. 1985, 38, 618-624.
27. Steen, V. M., O. A. Andreassen, A. K. Daly, T. Tefre, A. L. Børresen, J. R. Idle & A. K. Guldbrandsen. Detection of the poor metabolizer-associated CYP2D6(D)-gene deletion allele by long-PCR technology. Pharmacogenetics 1995, 5, 215-223.
28. Tucker, G. T., J. H. Silas, A. O. Iyun, M. S. Lennard & A. I. Smith: Polymorphic hydroxylation of debrisoquine in man. Lancet 1977, 2, 718.
29. Tybring, G. & L. Bertilsson: A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 1992, 2, 241-243.
30. Wedlund, P. J., W. S. Aslanian, C. B. McAllister, G. R. Wilkinson & R. A. Branch: Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Therap. 1984, 36, 773-780.
31. Wilkinson, G. R., F. P. Guengerich & R. A. Branch: Genetic polymorphism of S-mephenytoin hydroxylation. In: Pharmacogenetics of drug metabolism. Ed.: W. Kalow. Pergamon Press, New York 1992, p. 657-685.